Form 8-K - Current report:
SEC Accession No. 0000950170-23-028611
Filing Date
2023-06-16
Accepted
2023-06-16 16:13:28
Documents
13
Period of Report
2023-06-14
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ntla-20230614.htm   iXBRL 8-K 120671
2 EX-3.1 ntla-ex3_1.htm EX-3.1 17265
  Complete submission text file 0000950170-23-028611.txt   274554

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ntla-20230614.xsd EX-101.SCH 2468
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ntla-20230614_pre.xml EX-101.PRE 12050
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ntla-20230614_lab.xml EX-101.LAB 18988
7 EXTRACTED XBRL INSTANCE DOCUMENT ntla-20230614_htm.xml XML 5111
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

EIN.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37766 | Film No.: 231021241
SIC: 2835 In Vitro & In Vivo Diagnostic Substances